Allergan adds MAP to migraine plans

US maker of Botox pays a 60% premium for MAP Pharmaceuticals in a $958m deal to expand its offering of migraine headache treatments
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news